NuCana (NASDAQ:NCNA) Stock Price Up 0.9% – Time to Buy?
by Danessa Lincoln · The Markets DailyNuCana PLC Sponsored ADR (NASDAQ:NCNA – Get Free Report)’s share price rose 0.9% during trading on Thursday . The company traded as high as $2.17 and last traded at $2.15. Approximately 12,273 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 38,089 shares. The stock had previously closed at $2.13.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research report on Tuesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, NuCana has an average rating of “Sell”.
Get Our Latest Research Report on NCNA
NuCana Stock Performance
The firm has a market capitalization of $8.94 million, a price-to-earnings ratio of -0.02 and a beta of 1.79. The company’s fifty day moving average price is $1.94 and its 200 day moving average price is $3.11.
Institutional Inflows and Outflows
An institutional investor recently raised its position in NuCana stock. FNY Investment Advisers LLC boosted its holdings in NuCana PLC Sponsored ADR (NASDAQ:NCNA – Free Report) by 210.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the company’s stock after acquiring an additional 6,774 shares during the quarter. FNY Investment Advisers LLC owned 33.33% of NuCana worth $36,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 44.00% of the company’s stock.
NuCana Company Profile
NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.
At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.